These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10299510)

  • 1. The elimination of selected drug products from the Michigan Medicaid formulary: a case study.
    Smith DM; McKercher PL
    Hosp Formul; 1984 May; 19(5):366-72. PubMed ID: 10299510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary.
    Wang YR; Pauly MV; Lin YA
    Am J Manag Care; 2003 Oct; 9(10):686-96. PubMed ID: 14572179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlling prescription drug expenditures: a report of success.
    Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
    Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Washington State CARE Project: downstream cost changes associated with the provision of cognitive services by pharmacists.
    Smith DH; Fassett WE; Christensen DB
    J Am Pharm Assoc (Wash); 1999; 39(5):650-7. PubMed ID: 10533346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors.
    Wang YR; Pauly MV
    Manag Care Interface; 2005 Aug; 18(8):39-45. PubMed ID: 16127891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ripple effects of a restrictive Medicaid formulary.
    Grabowski H
    Am J Manag Care; 2003 Oct; 9(10):648-9. PubMed ID: 14572174
    [No Abstract]   [Full Text] [Related]  

  • 7. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a Medicaid database to analyze pharmaceutical services in long-term-care facilities.
    Lipowski EE; Wiederholt JB; Kreling DH; Collins TM
    Am J Hosp Pharm; 1986 Jun; 43(6):1467-72. PubMed ID: 3088992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copayment for pharmaceutical services in a Medicaid program.
    Nelson AA; Quick MR
    Contemp Pharm Pract; 1980; 3(1):37-42. PubMed ID: 10297666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing Medicaid drug expenditures.
    Sudovar SG; Rein SD
    J Health Hum Resour Adm; 1978 Nov; 1(2):200-30. PubMed ID: 10308767
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a pharmacy benefit to a managed Medicaid population.
    Smith WW; Perry SC
    Med Interface; 1995 Dec; 8(12):84-7, 97. PubMed ID: 10153524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
    Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
    Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Medicaid drug cost control experiences.
    Kennard LH; Platt WG
    Med Mark Media; 1979 Mar; 14(3):38, 40-3. PubMed ID: 10316799
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
    Seay M; Varma P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicaid formularies: a critical review of the literature.
    Jang R
    J Pharm Mark Manage; 1988; 2(3):39-61. PubMed ID: 10302873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.